Zimura
( DrugBank: - / KEGG DRUG: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 301 | 黄斑ジストロフィー | 6 |
301. 黄斑ジストロフィー
臨床試験数 : 46 / 薬物数 : 42 - (DrugBank : 11) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 67
Showing 1 to 6 of 6 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-004783-35-DE (EUCTR) | 10/07/201820180710 | 23/01/201820180123 | A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Autosomal Recessive Stargardt Disease A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimurain Subje ... | A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimur ... | Autosomal Recessive Stargardt Disease MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] Autosomal Recessive Stargardt Disease MedDRA version: 20.1;Level: PT;Classification code 10062766;Te ... | Product Name: Zimura Product Code: ARC1905 INN or Proposed INN: avacincaptad pegol Other descriptive name: ARC1905 20 MG/ML Product Name: Zimura Product Code: ARC1905 INN or Proposed INN: avacincaptad pegol Other descriptive na ... | IVERIC bio | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 70 | Phase 2 | United States;France;Hungary;Canada;Spain;Israel;Germany;United Kingdom;Italy | ||
| 2 | EUCTR2017-004783-35-IT (EUCTR) | 05/06/201820180605 | 25/01/202120210125 | A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Autosomal Recessive Stargardt Disease A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimurain Subje ... | A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease - A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subj A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimur ... | Autosomal Recessive Stargardt Disease MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] Autosomal Recessive Stargardt Disease MedDRA version: 20.1;Level: PT;Classification code 10062766;Te ... | Product Name: Zimura Product Code: [ARC1905] INN or Proposed INN: avacincaptad pegol Other descriptive name: ARC1905 Product Name: Zimura Product Code: [ARC1905] INN or Proposed INN: avacincaptad pegol Other descriptive ... | IVERIC bio, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 120 | Phase 2 | France;United States;Hungary;Canada;Spain;Israel;Germany;United Kingdom;Italy | ||
| 3 | EUCTR2017-004783-35-GB (EUCTR) | 29/05/201820180529 | 26/01/201820180126 | A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Autosomal Recessive Stargardt Disease A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimurain Subje ... | A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimur ... | Autosomal Recessive Stargardt Disease MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] Autosomal Recessive Stargardt Disease MedDRA version: 20.1;Level: PT;Classification code 10062766;Te ... | Product Name: Zimura Product Code: ARC1905 INN or Proposed INN: avacincaptad pegol Other descriptive name: ARC1905 20 MG/ML Product Name: Zimura Product Code: ARC1905 INN or Proposed INN: avacincaptad pegol Other descriptive na ... | IVERIC bio | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 70 | Phase 2 | United States;France;Hungary;Canada;Spain;Israel;Germany;Italy;United Kingdom | ||
| 4 | EUCTR2017-004783-35-ES (EUCTR) | 09/04/201820180409 | 02/02/201820180202 | A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Autosomal Recessive Stargardt Disease A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimurain Subje ... | A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimur ... | Autosomal Recessive Stargardt Disease MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] Autosomal Recessive Stargardt Disease MedDRA version: 20.1;Level: PT;Classification code 10062766;Te ... | Product Name: Zimura Product Code: ARC1905 INN or Proposed INN: avacincaptad pegol Other descriptive name: ARC1905 20 MG/ML Product Name: Zimura Product Code: ARC1905 INN or Proposed INN: avacincaptad pegol Other descriptive na ... | OPHTHOTECH CORPORATION | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 120 | Phase 2 | France;United States;Hungary;Canada;Spain;Israel;Germany;Italy;United Kingdom | ||
| 5 | EUCTR2017-004783-35-HU (EUCTR) | 21/03/201820180321 | 01/02/201820180201 | A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura in Subjects with Autosomal Recessive Stargardt Disease A Clinical Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimurain Subje ... | A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimur ... | Autosomal Recessive Stargardt Disease MedDRA version: 20.1;Level: PT;Classification code 10062766;Term: Stargardt's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] Autosomal Recessive Stargardt Disease MedDRA version: 20.1;Level: PT;Classification code 10062766;Te ... | Product Name: Zimura Product Code: ARC1905 INN or Proposed INN: avacincaptad pegol Other descriptive name: ARC1905 20 MG/ML Product Name: Zimura Product Code: ARC1905 INN or Proposed INN: avacincaptad pegol Other descriptive na ... | IVERIC bio | NULL | Not Recruiting | Female: yes Male: yes | 70 | Phase 2 | United States;France;Hungary;Canada;Spain;Israel;Germany;United Kingdom;Italy | ||
| 6 | NCT03364153 (ClinicalTrials.gov) | January 12, 201820180112 | 1/12/201720171201 | Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1) | A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimur ... | Stargardt Disease 1 | Drug: Zimura;Other: Sham | IVERIC bio, Inc. | NULL | Recruiting | 18 Years | 60 Years | All | 120 | Phase 2 | United States;Canada;France;Germany;Hungary;Israel;Italy;Spain;United Kingdom |